NK-001
PIPELINE
OT-A201
PARTNERSHIPS
NEWS & EVENTS
WHO WE ARE
We are a development stage oncology company, focusing on the identification of innovative technologies and the development of truly breakthrough medicines for the treatment of cancer.
Our company, led by an experienced team in translational science and drug development, acquires licenses for potential development candidates and invest in partners with transformative technology platforms.
We are located at Biopôle, a life sciences campus in Epalinges near Lausanne, Switzerland, we have an affiliate in Paris, France, and also operate from Taipei, Taiwan.
IDENTIFY promising projects
BUILD partnerships
ADVANCE cancer care
Apr 22, 2025
Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to
Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination
with Rituximab
Jan 24, 2024
Jul 24, 2023
Emercell NK-001 (OT-C001) project selected as part of France 2030 plan “Biotherapies and bioproduction of innovative therapies"
Read More...
Sep 23, 2022
Jun 08, 2021
Onward Therapeutics Signs an Exclusive Collaboration and Worldwide Option and License Agreement with Institut du Cancer de Montpellier
Read More...
May 04, 2021
Onward Therapeutics SA opened a wholly owned affiliate, Onward Therapeutics France SAS in Paris, France
Read More...
Feb 17, 2021
Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy
Read More...
Feb 16, 2021
Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology
Read More...
Feb 16, 2021
Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology
Read More...